Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT04654208

Swedish Ibrance Registries Insights (SIRI)

Conditions: Malignant Neoplasm of Breast

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 1500

Sponsor: Pfizer

Location: Pfizer Sweden Sollentuna

Summary

The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.

Eligibility Criteria

Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33) 2. Age ≥18 years at index date Exclusion Criteria: There are no exclusion criteria

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04654208). StuddyBuddy aggregates publicly available trial information.